AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$AGL

Agilon raises 2026 outlook to $5.88B revenue and $150M adjusted EBITDA while expecting 40%-50% ACO membership growth in 2027 (NYSE:AGL)

Agilon Health (AGL) raised its 2026 revenue outlook to $5.88B and adjusted EBITDA to $150M, citing strong Q3 performance. CEO Timothy O’Rourke attributed the increase to improved physician performance. The company also expects 40%-50% ACO membership growth in 2027.

Original reporting
seekingalpha.com
Published Nov 5, 2026, 12:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AGL
Bullish
high confidence
Mentioned
$AGL
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AGLBullishHigh
01

Why it matters

The guidance upgrade is expected to boost investor confidence and may trigger a price rally.

02

Market read

First‑report guidance lift for a mid‑cap healthcare firm; material for traders and analysts.

03

What to watch

Potential regulatory scrutiny of ACO contracts and the impact of broader Medicare policy changes.

Relevance 8/10Novelty 8/10Timing: post‑market release

Background

Agilon Health reported exceeding Q3 2026 guidance and announced an upgraded full‑year outlook.

Company-level read

Ticker impact

$AGLBullishHigh confidence
Context

Agilon Health (AGL) raised its 2026 revenue outlook to $5.88 B and adjusted EBITDA to $150 M, citing 40‑50% ACO membership growth in 2027.

Expected impact

likely upward pressure as investors price in higher revenue and earnings expectations

Evidence & confidence

The new outlook exceeds prior guidance and reflects significant membership growth, a material catalyst for valuation.

Market effects

Sector

Improved outlook may lift other ACO‑focused health‑care providers and related Medicare Advantage stocks.

Regional

Positive for U.S. healthcare sector, especially providers with similar membership models.

Global

Limited to U.S. healthcare investors; no direct global macro effect.

Counterpoint

What could challenge this read

If membership growth stalls or reimbursement rates tighten, the guidance lift could be premature.

Key entities

  • Company
    Agilon Health

    U.S. healthcare services provider listed on NYSE.

Read at source← All news

StoryAgilon Health reports Q3 2026 beat and raises full‑year revenue and EBITDA guidance

Also covered by

1 outlet

Related articles

$AGLMed

Agilon Health Inc (AGL) (Q3 2026) Earnings Call Highlights: Guidance Raised as Adjusted

Agilon Health Inc (AGL) reported Q3 2026 earnings, beating guidance with adjusted EBITDA of $64M, up from -$91M in Q3 2025. The company raised full-year 2026 guidance and expects 40-50% ACO membership growth in 2027. However, Medicare Advantage membership declined 10% YoY, and medical costs remain high. The company plans to expand into new markets starting in 2028. AGL ended Q3 with $312M in cash and raised its year-end cash outlook to at least $175M.

finance.yahoo.com
$AGLMed

Agilon Health Q3 Earnings Call Highlights

Agilon Health (NYSE: AGL) reported a medical services expense ratio of 88.5% in Q3, down from 104% a year earlier. The company exceeded adjusted EBITDA guidance by $64M, citing favorable risk adjustments and cost trends. Agilon raised its full-year cash outlook to at least $175M and expects 40-50% ACO membership growth in 2027. CEO Tim O'Rourke highlighted clinical program expansions and plans for new market partnerships.

finance.yahoo.com
$AGLHighAI 8/10

Agilon: Q3 Earnings Snapshot

Agilon Health Inc. (AGL) reported Q3 net income of $34.9M, or $1.97 per share, beating analyst expectations of a loss. Revenue was $1.52B, also exceeding forecasts. The company expects full-year revenue between $5.87B and $5.89B. Shares have increased fivefold in the past year, closing at $95.76 on Wednesday.

finance.yahoo.com
$AGLMed

agilon health, inc. (AGL): Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year Increases Full Year 2026 Guidance to Reflect Positive Third Quarter Results

agilon health, inc. (AGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 agilon health Reports Third Quarter 2026 Results Revenue increased 6% to $1.52 billion Compared to the Same Period in the Prior Year Increases Full Year 2026 Guidance to Reflect Positive Third Quarter Results Westerville, O.H., November 4, 2026 – agilon health, inc.

SEC EDGAR 8-K